Cn /En

News Center

——

Company news

Industry news

InnoModels: Introduction of iHuPDX model features

Author:

InnoModels

Release time:

2024-03-11

With the rapid development of biotechnology, people's understanding of diseases and means of treatment are also deepening. Against this background, the iHuPDX model introduced by InnoModels has opened up a new path for biomedical research with its unique features.
I. Homogenized modeling of the same batch of samples
InnoModels Bio's iHuPDX model ensures homogenization of samples between batches by modeling cell suspensions. This means that there is a high degree of consistency in the growth rate and biological characteristics of individual samples within the same batch. This homogenization modeling method not only lays a solid foundation for the stability of the model, but also provides a strong guarantee for the reliability and reproducibility of the experimental results.

Stability and Consistency of Same-Generation Transmission
The homogenization of the same batch of samples ensures the stability of the same generation and after the transmission. In the long-term research process, the iHuPDX model can maintain consistent growth and efficacy characteristics, which makes the experimental results more reliable. This stability and consistency of sibling transmission makes the model have a wide range of application prospects in the fields of drug development and disease treatment.
Early and uniform growth, optimal efficacy experimental window
The iHuPDX model of InnoModels Biotechnology provides an optimal experimental window for efficacy experiments by realizing uniform growth at an early stage. Conducting efficacy experiments in the P2-P5 generation can more accurately reflect the therapeutic effect of the drug on the disease, providing strong support for drug development. At the same time, the early uniform growth characteristics also make the model more advantageous in disease simulation and treatment strategy research.
In conclusion, the iHuPDX model of InnoModels provides a new perspective and tool for biomedical research with its unique features of homogenization modeling of samples from the same batch, stability and consistency of sibling transmission, and early uniform growth. The application of this model is expected to promote the development of personalized medicine and make greater contributions to human health.

InnoModels: Features of CDX in vivo drug efficacy test platform

InnoModels: Introducing the Benefits of In Situ Surgical Models

InnoModels: Features of CDX in vivo drug efficacy test platform

InnoModels: Introducing the Benefits of In Situ Surgical Models

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License